Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure

European Journal of Heart Failure

Volumn 15, Issue 12, 2013, Pages 1390-1400

  Behnes, Michael ^a   Brueckmann, Martina ^a,b   Lang, Siegfried ^a   Espeter, Florian ^a   Weiss, Christel ^c   Neumaier, Michael ^a   Ahmad Nejad, Parviz ^d   Borggrefe, Martin ^a   Hoffmann, Ursula ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HELIOS KLINIKUM WUPPERTAL   (Germany)

Author keywords

Acute congestive heart failure; Mortality; NT proBNP; Osteopontin; Prognosis; Rehospitalization

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; HEMOGLOBIN; OSTEOPONTIN;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MORTALITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DYSPNEA; EMERGENCY WARD; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ACUTE CONGESTIVE HEART FAILURE; MORTALITY; NT-PROBNP; OSTEOPONTIN; PROGNOSIS; REHOSPITALIZATION;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CONFIDENCE INTERVALS; DYSPNEA; EDEMA, CARDIAC; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; OSTEOPONTIN; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84890085360     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft112     Document Type: Article

References (30)

1. Opie LH, Commerford PJ, Gersh BJ, PfefferMA. Controversies in ventricular remodelling. Lancet 2006;367:356-367
2. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007;27: 2302-2309
3. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006;99:1044-1059
4. Xie Z, Singh M, Singh K. Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension 2004;44:826-831
5. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E, Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997;96:3063-3071
6. Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001;88:1080-1087
7. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, Bing OH, Colucci WS. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 1999;33:663-670
8. Psarras S, Mavroidis M, Sanoudou D, Davos CH, Xanthou G, Varela AE, Panoutsakopoulou V,Capetanaki Y. Regulation of adverse remodelling by osteopontin in a genetic heart failure model. Eur Heart J 2012;33:1954-1963
9. Kaye DM, Khammy O, Mariani J, Maeder MT. Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure. Eur J Heart Fail 2013;15:292-298
10. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, NielsenOW, Orn S, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869
11. Behnes M, Brueckmann M, Ahmad-Nejad P, Lang S,Wolpert C, Elmas E, Kaelsch T, Gruettner J, Weiss C, Borggrefe M, Neumaier M. Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. Int J Cardiol 2009;135:165-174
12. Behnes M, Lang S, Breithardt OA, Kaden JJ, Haghi D, Ahmad-Nejad P, Elmas E, Wolpert C, Borggrefe M, Neumaier M, Brueckmann M. Association of NT-proBNP with severity of heart valve disease in a medical patient population presenting with acute dyspnea or peripheral edema. J Heart Valve Dis 2008;17:557-565
13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013. Epub 2013/06/07
14. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-193
15. Human Osteopontin (OPN) Quantikine ELISA Kit.&2010R&D Systems, Inc.;Available from: http://www.rndsystems.com/pdf/dost00.pdf
16. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843
17. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of anewmarker: from area under theROCcurve to reclassification and beyond. Stat Med 2008;27:157-172;discussion 207-212
18. Rosenberg M, Meyer FJ, Gruenig E, Lutz M, Lossnitzer D, Wipplinger R, Katus HA, Frey N. Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension. Eur J Clin Invest 2012;42:933-942
19. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A, Giannitsis E, Katus HA, Frey N. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008;1:43-49
20. Rosenberg M, Meyer FJ, Gruenig E, Schuster T, Lutz M, Lossnitzer D, Wipplinger R, Katus HA, Frey N. Osteopontin (OPN) improves risk stratification in pulmonary hypertension (PH). Int J Cardiol 2012;155:504-505
21. Krum H, Elsik M, Schneider HG, Ptaszynska A, Black M, Carson PE, Komajda M, Massie BM, McKelvie RS, McMurray JJ, Zile MR, Anand IS. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the 1-PRESERVE collagen substudy. Circ Heart Fail 2011;4:561-568
22. Francia P, Balla C, Ricotta A, Uccellini A, Frattari A, Modestino A, Borro M, Simmaco M, Salvati A, De Biase L, Volpe M. Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. Int J Cardiol 2011;153:306-310
23. Schipper ME, Scheenstra MR, van Kuik J, van Wichen DF, van der Weide P, Dullens HF, Lahpor J, de Jonge N,De Weger RA. Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support. J Heart Lung Transplant 2011;30:805-810
24. Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM. Can emerging biomarkers of myocardial remodeling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011;13:1087-1095
25. Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M. Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiology Rev 2010;18: 125-131
26. Stawowy P, Blaschke F, Pfautsch P, Goetze S, Lippek F, Wollert-Wulf B, Fleck E, Graf K. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail 2002;4:139-146
27. Singh M, Foster CR, Dalal S, Singh K. Role of osteopontin in heart failure associated with aging. Heart Fail Rev 2010;15:487-494
28. Maisel A, Mueller C,Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C,Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-2076
29. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdes M, Januzzi JL. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011;13: 718-725
30. Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N, Clopton P, van Veldhuisen DJ. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011;13:846-851